The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries

Author:

,Adegboyega Temitope Adesiji,Adejuyigbe Ebunoluwa Aderonke,Adesina Olubukola Adeponle,Adeyemi Babalola,Ahmed Salahuddin,Akinkunmi Francis,Aluvaala Jalemba,Anyabolu Henry,Ariff Shabina,Arya Sugandha,Awowole Ibraheem,Ayede Adejumoke Idowu,Babar Neelofur,Bachani Sumitra,Bahl Rajiv,Baqui Abdullah H.,Chellani Harish,Chowdhury Saleha Begum,Coppola Lynn M.,Cousens Simon,Debata Pradeep K.,de Costa Ayesha,Dhaded Sangappa M.,Donimath Kasturi V.,Falade Adegoke Gbadegesin,Goudar Shivaprasad S.,Gupta Shuchita,Gwako George N.,Irinyenikan Theresa Azonima,Isah Dennis Anthony,Jabeen Nigar,Javed Arshia,Joseph Naima T.,Khanam Rasheda,Kinuthia John,Kuti Oluwafemi,Lavin Tina,Laving Ahmed R.,Maranna Sandhya,Minckas Nicole,Mittal Pratima,Mohan Diwakar,Nausheen Sidrah,Nguyen My Huong,Oladapo Olufemi T.,Olutekunbi Olanike Abosede,Oluwafemi Rosena Olubanke,Osoti Alfred,Pujar Yeshita V.,Qureshi Zahida P.,Rao Suman P. N.,Sarrassat Sophie,Shahed M. A.,Shahidullah Mohammod,Sheikh Lumaan,Somannavar Manjunath S.,Soofi Sajid,Suri Jyotsna,Vernekar Sunil S.,Vogel Joshua P.,Wadhwa Nitya,Wari Prakash K.,Were Fred,Wylie Blair J.

Abstract

Abstract Background Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antenatal corticosteroids (ACS) prevent mortality and respiratory morbidity when administered to women at high risk of an early preterm birth, i.e. < 34 weeks’ gestation. However, the benefits and risks of ACS in the late preterm period are less clear; both guidelines and practices vary between settings. Emerging evidence suggests that the benefits of ACS may be achievable at lower doses than presently used. This trial aims to determine the efficacy and safety of two ACS regimens compared to placebo, when given to women with a high probability of late preterm birth, in hospitals in low-resource countries. Methods WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phosphate 4 × 2 mg q 12 h. The trial is being conducted across seven sites in five countries—Bangladesh, India, Kenya, Nigeria, and Pakistan. Eligible women are those with a gestational age between 34 weeks 0 days and 36 weeks 5 days, who have a high probability of preterm birth between 12 h and 7 days (up to 36 weeks 6 days gestation). The primary outcome is a composite of stillbirth or neonatal death within 72 h of birth or use of newborn respiratory support within 72 h of birth or prior to discharge from hospital, whichever is earlier. Secondary outcomes include safety and health utilization measures for both women and newborns. The sample size is 13,500 women. Discussion This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmacokinetic studies. The results of this trial will provide robust critical evidence on the safe and appropriate use of ACS in the late preterm period internationally. Trial registration ISRCTN11434567. Registered on 7 June 2021.

Funder

Bill and Melinda Gates Foundation

Publisher

Springer Science and Business Media LLC

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3